Overall rank by patents
#37,805
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Teika Pharmaceutical Co., Ltd.
USPTO PatentsView assignee record - 7 granted patents across 10 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
7
Total patents granted
10
CPC technology areas
16.3
Avg claims per patent
+150%
5-year filing velocity
The verdict
Teika holds 7 US patents across 10 technology areas, rank #37,805 of 50,000 tracked assignees.
- #37,805
- of 50,000 US assignees by volume
- Top 33%
- by Innovation Score (41.5/100)
- 16.3
- avg claims per patent
- +150%
- filing velocity, last 5 yrs
Portfolio overview
Teika Pharmaceutical Co., Ltd. has been granted 7 US utility patents between 2016 and 2025, placing Teika Pharmaceutical Co., Ltd. at rank #37,805 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Teika Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Teika sits between Technological Educational Institute OF Crete (7 patents, rank #37,801) and Teloip Inc. (7 patents, rank #37,809) - the closest US assignees by grant volume. The composite Innovation Score of 41.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 2 in the 2015–2019 window, a +150% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Teika Pharmaceutical Co., Ltd.'s 16.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Teika Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.
Who files at Teika's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Technological Edu…
TECHNOLOGICAL EDUCATIONAL INSTITUTE OF CRETE
7 patents
- Technological Uni…
TECHNOLOGICAL UNIVERSITY DUBLIN
7 patents
- Tecnologia Bancar…
TECNOLOGIA BANCARIA S.A.
7 patents
- Tecnoviv
TECNOVIV LLC
7 patents
- Tekelec Global
TEKELEC GLOBAL, INC.
7 patents
- Teleport MED
TELEPORT MED, LLC
7 patents
- Televic Conference
TELEVIC CONFERENCE
7 patents
- Teloip
TELOIP INC.
7 patents
- Teika Pharmaceuti… ◀
TEIKA PHARMACEUTICAL CO., LTD.
7 patents
What this shows Teika holds 7 patents at rank #37,805, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Teika
By rank, the assignees closest to #37,805 in granted patent volume.
- Technological Educational Institute OF Crete #37,801 · 7 patents
- Technological University Dublin #37,802 · 7 patents
- Tecnologia Bancaria S.a. #37,803 · 7 patents
- Tecnoviv Llc #37,804 · 7 patents
- Tekelec Global, Inc. #37,806 · 7 patents
- Teleport MED, Llc #37,807 · 7 patents
- Televic Conference #37,808 · 7 patents
- Teloip Inc. #37,809 · 7 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Teika's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Teika's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
41 Top 33% higher than 67% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 28.6% |
| 2021 | 1 | 14.3% |
| 2022 | 1 | 14.3% |
| 2023 | 1 | 14.3% |
| 2025 | 2 | 28.6% |
Which technologies does Teika Pharmaceutical Co., Ltd. patent most?
Top 10 of 10 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Teika Pharmaceutical Co., Ltd. hold?
Teika Pharmaceutical Co., Ltd. holds 7 US granted patents filed between 2016 and 2025, spanning 10 technology areas.
What is Teika Pharmaceutical Co., Ltd.'s Innovation Score?
Teika Pharmaceutical Co., Ltd. has an Innovation Score of 41.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Teika Pharmaceutical Co., Ltd. focus on?
Teika Pharmaceutical Co., Ltd.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 6 patents. The company has filed patents in 10 CPC subclasses total.
Is Teika Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?
Teika Pharmaceutical Co., Ltd.'s recent filing velocity is +150% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Teika Pharmaceutical Co., Ltd.'s patents?
Teika Pharmaceutical Co., Ltd.'s patents average 16.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Teika Pharmaceutical Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Teika's 7 grants land it in the top 33% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Teika ranks #37,805 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.